Symbols

EYPT

EyePoint·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EYPT

Eyepoint, Inc.

A pharmaceutical company that focused on ophthalmic treatments

Industry

Pharmaceutical

Established Date

03/19/2008

Listing Date

06/20/2008

Exchange

NASDAQ Stock Exchange

Full-time Employees

214

Fiscal Year Ends

12-31

Website

www.eyepointpharma.com

Security Type

Common stock

Office address

480 Pleasant Street, Watertown, MA 02472

Business

Introduction

EyePoint, Inc., incorporated in Delaware on March 19, 2008, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies to help improve the lives of patients with severe retinal diseases. The Company utilizes its proprietary biodegradable Durasert E technology for continuous intraocular drug delivery, addressing the challenges posed by frequent intravitreal injections. Its lead product candidate, DURAVYU, is an investigational therapy for the treatment of vascular endothelial growth factor-mediated retinal diseases.

Company Financials

EPS

EYPT has released its 2025 Q4 earnings. EPS was reported at -0.81, versus the expected -0.75, missing expectations. The chart below visualizes how EYPT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EYPT has released its 2025 Q4 earnings report, with revenue of 620.00K, reflecting a YoY change of -94.65%, and net profit of -67.61M, showing a YoY change of -63.31%. The Sankey diagram below clearly presents EYPT's revenue sources and cost distribution.